Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: Clinical and biochemical presentation

Hypertension

Volumn 57, Issue 6, 2011, Pages 1117-1121

  Aglony, Marlene ^a   Martínez Aguayo, Alejandro ^a   Carvajal, Cristian A ^a   Campino, Carmen ^a   García, Hernán ^a   Bancalari, Rodrigo ^a   Bolte, Lillian ^a   Avalos, Carolina ^b   Loureiro, Carolina ^a   Trejo, Pamela ^a   Brinkmann, Karin ^c   Giadrosich, Vinka ^d   Mericq, Verónica ^e   Rocha, Ana ^e   Avila, Alejandra ^e   Perez, Viviana ^a   Inostroza, Andrea ^a   Fardella, Carlos E ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD DE ANTOFAGASTA   (Chile)

^c Hospital Regional de Punta Arenas   (Chile)

^d UNIVERSIDAD DE VALPARAÍSO   (Chile)

^e UNIVERSITY OF CHILE   (Chile)

Author keywords

aldosterone; arterial hypertension; children; familial hyperaldosteronism; glucocorticoid remediable aldosteronism

Indexed keywords

ALDOSTERONE SYNTHASE; DEXAMETHASONE; DNA; HYDROCORTISONE; POTASSIUM; SPIRONOLACTONE;

ADOLESCENT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CHILD; CHILE; DNA DETERMINATION; FAMILIAL HYPERALDOSTERONISM TYPE 1; FEMALE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 85027923747     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.168740     Document Type: Article

References (23)

1. Martinez-Aguayo A, Fardella C. Genetics of hypertensive syndrome. Horm Res. 2009;71:253-259.
2. Ogishima T, Shibata H, Shimada H, Mitani F, Suzuki H, Saruta T, Ishimura Y. Aldosterone synthase cytochrome P-450 expressed in the adrenals of patients with primary aldosteronism. J Biol Chem. 1991;266: 10731-10734. (Pubitemid 21906864)
3. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11-hydroxylase/aldosterone synthase gene causes glucocorticoid- remediable aldosteronism and human hypertension. Nature. 1992;355:262-265.
4. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids. 1995;60:48-51.
5. Pizzolo F, Trabetti E, Guarini P, Mulatero P, Ciacciarelli A, Blengio GS, Corrocher R, Olivieri O. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting. J Hum Hypertens. 2005;19:325-327. (Pubitemid 40514912)
6. Dluhy R, Anderson B, Harlin B, Ingelfinger J, Lifton R. Glucocorticoidremediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr. 2001;138:715-720. (Pubitemid 32417674)
7. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension. 2000;36:495-500.
8. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291-303.
9. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 suppl IV report):555-576.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
11. Martinez-Aguayo A, Aglony M, Campino C, Garcia H, Bancalari R, Bolte L, Avalos C, Loureiro C, Carvajal CA, Avila A, Perez V, Inostroza A, Fardella CE. Aldosterone, plasma renin activity, and aldosterone/renin ratio in a normotensive healthy pediatric population. Hypertension. 2010; 56:391-396.
12. Urbina E, Alpert B, Flynn J, Hayman L, Harshfield GA, Jacobson M, Mahoney L, McCrindle B, Mietus-Snyder M, Steinberger J, Daniels S; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee. Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension. 2008;52:433-451.
13. Prat MH, Valdés SG, Román AO, Zarate MLH. Update of consensus recommendations of the Chilean Hypertension Society about ambulatory blood pressure monitoring. Rev Med Chil. 2009;137:1235-1247.
14. Batista DL, Riar J, Keil M, Stratakis CA. Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics. 2007;120:e575-e586. (Pubitemid 47358270)
15. Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161-165. (Pubitemid 36944590)
16. Higgins DG. CLUSTAL V: multiple alignment of DNA and protein sequences. Methods Mol Biol. 1994;25:307-318.
17. Montero J, Soto J, Fardella C, Foradori A, Valdés G. Measurement of low levels of plasma renin activity: a methodological improvement. Rev Med Chil. 1998;126:151-154.
18. Carvajal CA, Stehr CB, González PA, Riquelme EM, Montero T, Santos MJ, Kalergis AM, Fardella CE. A de novo unequal cross-over mutation between CYP11B1 and CYP11B2 genes causes familial hyperaldosteronism type I. J Endocrinol Invest. 2010;July 13 [Epub ahead of print].
19. Fallo F, Pilon C, Williams TA, Sonino N, Morra Di Cella S, Veglio F, De Iasio R, Montanari P, Mulatero P. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. J Hum Hypertens. 2004;18:47-51. (Pubitemid 38165521)
20. Litchfield WR, Coolidge C, Silva P, Lifton RP, Fallo F, Williams GH, Dluhy RG. Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoidremediable aldosteronism. J Clin Endocrinol Metab. 1997;82:1507-1510. (Pubitemid 27200426)
21. McMahon G, Dluhy R. Glucocorticoid-remediable aldosteronism. Cardiol Rev. 2004;12:1-5.
22. Fardella C, Pinto M, Mosso L, Gómez-Sánchez C, Jalil J, Montero J. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene. J Clin Endocrinol Metab. 2001;86: 4805-4807. (Pubitemid 33020523)
23. Stehr CB, Carvajal CA, Lacourt P, Alcaíno H, Mellado R, Cattani A, Mosso LM, Lavandera S, Fardella CE. Subclinical endothelial inflammation markers in a family with type I familial hyperaldosteronism caused by a de novo mutation. Rev Med Chil. 2008;136:1134-1140.